Візит лікаря | ціна за запитом |
Хіміотерапія | $2655.01 - $3717.02 |
Хіміотерапія при раку молочної залози | $3717.02 - $5841.03 |
Променева терапія при раку прямої кишки | $16992.08 - $19116.09 |
Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the Bone Marrow Transplantation (Transplant) Unit for 13 years in Allogeneic (unrelated and intrafamilial), Autologous (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic stem cell transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.
MEDICAL AREAS OF INTEREST
Healthy baby follow-up and vaccinations
Lymph node enlargement
Pediatric patients with anemia (anemia)
Leukemia
Lymphoma
Bone Marrow Transplant
ITP
Thalassemias
Hemophiliacs
Solid tumors
Hemangioma
Childhood blood disorders
Children with frequent infections
Fever of unknown origin
Malnutrition in children
Читати даліВізит лікаря | ціна за запитом |
Хіміотерапія | $1500 - $2500 |
Імунотерапія Кейтрудой (Пембролізумаб) | $5800 - $6000 |
Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.
He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.
MEDICAL INTERESTS
Clotting Disorders (Thrombophilia)
Bleeding Disorders
Myeloproliferative Diseases
Anemias (Anemia)
Acute and Chronic Leukemias
lymphomas
Bone marrow transplantation
Читати даліВізит лікаря | ціна за запитом |
Хіміотерапія | $1500 - $2500 |
Імунотерапія Кейтрудой (Пембролізумаб) | $5800 - $6000 |
Assoc. Prof. Ali Eser received his medical education at Uludağ University Faculty of Medicine; He completed his internal medicine residency training at Istanbul Training and Research Hospital and his hematology residency training at Marmara University.
Afterward, he completed his compulsory service at Marmara University Hematology Clinic, firstly at Çanakkale University and then at Bezmialem Vakıf University. He served as a lecturer. After working as a hematology specialist and assistant physician in charge of the adult bone marrow transplant unit for 2 years at Hisar Intercontinental Hospital, he worked as a lecturer at Bezmialem Vakıf University and in the adult bone marrow transplant unit at Istanbul Yeniyüzyıl University, and finally for 1 year. He worked as the responsible physician of the adult bone marrow transplant unit at Liv Hospital Gaziantep Hospital for some time. He received the title of associate professor in March 2022.
Читати даліВізит лікаря | ціна за запитом |
Хіміотерапія | $1500 - $2500 |
Імунотерапія Кейтрудой (Пембролізумаб) | $5800 - $6000 |
Education:
2015
Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology
2010
Dokuz Eylül University, Medical Faculty, Internal Medicine
2005
Hacettepe University, Medical Faculty,
Experience:
2024 –
Istanbul Florence Nightingale Hospital
2017 – 2024
Bağcılar Medipol University Hospital
2017 – 2017
Fırat University
2015 - 2017
Fırat University
2014 - 2015
Mayo Clinic
Publications:
18 Articles Published in International Peer-Reviewed Journals
26 Abstracts and Books Presented at International Scientific Conferences
7 Articles Published in National Peer-Reviewed Journals
51 Abstracts Presented at National Scientific Conferences
Читати даліEducation and Expertise
Ankara University Faculty of Medicine - Medical Education
Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization
Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty
Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training
Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training
Experience
Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant
Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant
Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014
Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014
Gazi University Faculty of Health Sciences Dean (founder) 2008-2012
Professional Memberships
Turkish Hematology Association
Bilimsel Yayınları
1. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2. Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3. Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4. Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201.
5. Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7. Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80.
8. van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9. Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90.
10. Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7.
11. Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12. Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40.
13. Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14. Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015 Apr 28.
15. Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20.
16. Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17. Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18. Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19. Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20. Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22. Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23. Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62.
24. Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25. Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318 Pages 323 – 324
26. Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27. Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28. Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29. Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30. Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31. Keser I, Suyani E, Aki SZ, Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32. Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC. Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33. Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34. Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35. Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36. Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37. Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38. Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39. Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40. Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41. Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42. Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43. Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44. Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45. Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46. Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47. Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48. Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49. Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
50. Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51. Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52. Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53. Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54. Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55. Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56. Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57. Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58. Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60. Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61. Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62. Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63. Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64. Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65. Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66. Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67. Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68. Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69. Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.
Візит лікаря | ціна за запитом |
Хіміотерапія | $4000 - $8500 |
Доктор Дрор Левін є старшим педіатром і директором відділень захворювань крові та лікування раку кісток (саркоми) у дитячій лікарні «Дана» та медичному центрі «Сураскі» відповідно. Він спеціаліст з педіатрії, гематології та онкології, має додатковий досвід навчання за кордоном в Ортопедичному інституті Ріццолі в Італії.
Читати даліДоктор Херішану Яїр - гематолог із 25-річним досвідом, що спеціалізується на хронічному лімфоцитарному лейкозі (ХЛЛ). Він пропонує широкий спектр методів лікування, включно з трансплантацією кісткового мозку, імунотерапією препаратом Keytruda, CAR T-клітинною терапією і хіміотерапією лейкозу. Він був удостоєний кількох нагород, зокрема премії за дослідження молодих дослідників, премії за клінічну майстерність і премії Клітцберга в галузі онкології.
Читати даліун-т-проф. Доктор Вольфганг Йоганнес Кьостлер є сертифікованим спеціалістом із внутрішньої медицини, гематології/онкології та інтенсивної терапії, який спеціалізується на гематології та внутрішній онкології, інтенсивній терапії. Він є одним із найкращих спеціалістів-онкологів з раку молочної залози та саркоми, має великий досвід у цій галузі та отримав дипломи Віденського медичного університету та Наукового інституту Вейцмана. Він також пройшов спеціальну підготовку в онкологічному центрі Memorial Sloan-Kettering і Royal Prince Alfred Hospital.
Читати даліПрофесор Драч є фахівцем з онкології зі ступенем доктора філософії Віденського медичного університету. Він має досвід досліджень, внутрішньої медицини, гематологічної онкології, харчування та способу життя при раку. Він є директором приватної клініки Йозефштадт у Відні та членом ради директорів Австрійського товариства гематології та онкології. Опублікував понад 120 наукових праць і прочитав понад 200 лекцій/доповідей.
Читати даліMedical Fields of Interest:
Chronic Leukemia (Chronic Lymphocytes Leukemia/ Chronic Myeloid Leukemia)
Chronic Myeloproliferative Diseases (Polistemia Vera, Essential Thrombocytosis, Myelofibrosis etc.)
Lymphoma (Hodgkin’s and Non-Hodgkin’s)
Multiple Myeloma
Education:
Ege University Faculty of Medicine Medical Doctor 1999 - 2005
Pamukkale University Specialist in Internal Medicine 2006 - 2011
Pamukkale University Hematologist 2011 - 2014
ESCCA Summer School On Cytometry/PRAGUE (May 2014)
Istanbul Training and Research Hospital Hematology Clinic Associate Professor 2018
Experience:
Selçuk University Faculty of Medicine Hospital 2015
Pamukkale University Internal Medicine Residency Training 2016-2011
Denizli Sarayköy State Hospital 2011-2011
Pamukkale University Hematology Minor Residency Training 2011-2014
Istanbul Training and Research Hospital Hematology Clinic Specialist Doctor 2015-2020
Istanbul Training and Research Hospital Hematology Clinic Responsible Authority 2015-2020
Istanbul Training and Research Hospital Hematology Clinic Responsible Authority/ Lecturer 2019-2020
Istanbul Başakşehir Çam and Şakura City Hospital Hematology Clinic Lecturer 2020-2020
Liv Hospital Ulus 2020-
Memberships:
Turkish Society of Hematology
The Society of Hematological Education and Research (Member of The Board of Directors
Читати даліEDUCATION | |
| |
WORK EXPERIENCES & PRACTICES | |
| |
OTHER EXPERIENCES | |
2015-2017 | Instructor nursing student at Sai noi hospital and Bangbuatong hospital |
2015 | Member of Pharmacy and Therapeutics Committee at Bangbuatong hospital |
2015 | Emergency Medicine, organized by Phramongkutklao hospital |
2016 | Update in internal medicine, organized by Siriraj hospital |
2016 | Ambulatory medicine, organized by Chulalongkorn-Ramathibodi-Siriraj hospita |
2016 | 5th ECG workshop, organized by Chulalongkorn hospital |
ACADEMIC ACHIEVEMENTS | |
Co-author in: Development and validation of a cancer-associated venous thromboembolism clinical risk prediction (CAT-CR) model >> waiting for publication |
Професор Бош є відомим лідером у галузі хронічної лімфолейкемії (ХЛЛ) і проводить клінічні та фундаментальні дослідження ХЛЛ та інших лімфопроліферативних захворювань, зосереджуючись на молекулярному патогенезі ХЛЛ і нових терапевтичних підходах. Він опублікував понад 100 статей у престижних журналах і є професором гематології в університетській лікарні Vall d'Hebron у Барселоні.
Читати далі